{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:18:44Z","timestamp":1783610324854,"version":"3.55.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Risperidone is used as an adjunctive treatment for treatment-resistant depression, yet the therapeutic drug monitoring guidelines only include therapeutic reference ranges for schizophrenia. No therapeutic reference range for risperidone has been established for depressive disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a retrospective observational study involving inpatients who were administered risperidone from 2015 to 2020. Serum concentrations of the active moiety (AM) of risperidone (risperidone and its main metabolite 9-hydroxyrisperidone) were compared between patients suffering from schizophrenia spectrum disorders (SSD) and depression, as well as between nonpsychotic and psychotic depressive patients. In the depression cohort, associations between AM serum levels and treatment efficacy were assessed using the Clinical Global Impression\u2013Improvement scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 401 inpatients were included; of which, 220 were diagnosed with depressive disorders (ICD-10: F32\/F33), consisting of 40 with psychotic features, and 181 with SSD. AM serum concentration was significantly higher in patients with SSD compared with those with depression with or without psychotic symptoms (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). In total, 50% of the patients with depressive disorders with or without psychotic features were successfully treated with lower doses and serum concentrations than those administered to patients with SSD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Therapeutic reference ranges established for SSD cannot be applied to the treatment of depressive disorders. According to the recommendation rules of the therapeutic drug monitoring Task Force of the Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie, we suggest a preliminary therapeutic reference range of 10\u201330 ng\/mL (recommendation level 3) for risperidone as a treatment for depressive disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001507","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:00:10Z","timestamp":1783609210000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Risperidone Serum Levels in Depression: Insights From a Retrospective Therapeutic Drug Monitoring Study"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8067-4029","authenticated-orcid":false,"given":"Melike","family":"Kucukkarapinar","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy, University of W\u00fcrzburg, W\u00fcrzburg;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohler","family":"Meike","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy, University of W\u00fcrzburg, W\u00fcrzburg;"},{"name":"Department of Psychiatry and Psychotherapy Medical Center, University of Freiburg Faculty of Medicine, University of Freiburg, Freiburg;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weber","family":"Heike","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy, University of W\u00fcrzburg, W\u00fcrzburg;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Unterecker","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy, University of W\u00fcrzburg, W\u00fcrzburg;"},{"name":"Department of Psychiatry and Psychotherapy, Klinikum Bamberg, Bamberg; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Deckert","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy, University of W\u00fcrzburg, W\u00fcrzburg;"},{"name":"Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universit\u00e4t W\u00fcrzburg, W\u00fcrzburg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Walther","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy, University of W\u00fcrzburg, W\u00fcrzburg;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"Scherf-Clavel","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy, University of W\u00fcrzburg, W\u00fcrzburg;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"R1-20260709","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR*D project results: a comprehensive review of findings","volume":"9","author":"Warden","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"R2-20260709","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1586\/ern.09.53","article-title":"Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms","volume":"9","author":"Kurian","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"R3-20260709","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4088\/JCP.v69n0805","article-title":"Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study","volume":"69","author":"Reeves","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R5-20260709","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1755-5949.2011.00234.x","article-title":"Treatment strategies for dosing the second generation antipsychotics","volume":"17","author":"Schwartz","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"R6-20260709","first-page":"3","article-title":"Contrasting typical and atypical antipsychotic drugs","volume":"19","author":"Meltzer","year":"2021","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"R7-20260709","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-147-9-200711060-00003","article-title":"Risperidone for treatment-refractory major depressive disorder: a randomized trial","volume":"147","author":"Mahmoud","year":"2007","journal-title":"Ann Intern Med"},{"key":"R8-20260709","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1345\/aph.1P397","article-title":"Use of risperidone as augmentation treatment for major depressive disorder","volume":"45","author":"Owenby","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R9-20260709","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpsychires.2008.05.003","article-title":"A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression","volume":"43","author":"Keitner","year":"2009","journal-title":"J Psychiatr Res"},{"key":"R10-20260709","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","article-title":"Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis","volume":"302","author":"Nu\u00f1ez","year":"2022","journal-title":"J Affect Disord"},{"key":"R11-20260709","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/ph17050642","article-title":"Therapeutic drug monitoring in psychiatry: enhancing treatment precision and patient outcomes","volume":"17","author":"Biso","year":"2024","journal-title":"Pharmaceuticals"},{"key":"R12-20260709","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R13-20260709","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2013.243","article-title":"Comments on KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"84","author":"Andrassy","year":"2013","journal-title":"Kidney Int"},{"key":"R15-20260709","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jpsychires.2010.03.006","article-title":"Response and remission criteria in major depression\u2014a validation of current practice","volume":"44","author":"Riedel","year":"2010","journal-title":"J Psychiatr Res"},{"key":"R16-20260709","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/YIC.0000000000000250","article-title":"Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2","volume":"34","author":"Scherf-Clavel","year":"2019","journal-title":"Int Clin Psychopharmacol"},{"key":"R20-20260709","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/FTD.0000000000001264","article-title":"How to determine a therapeutic reference range for a psychotropic drug systematically? Recommendations of the TDM task force of the AGNP","volume":"47","author":"Hart","year":"2025","journal-title":"Ther Drug Monit"},{"key":"R21-20260709","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00702-022-02485-6","article-title":"Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone","volume":"129","author":"Taurines","year":"2022","journal-title":"J Neural Transm"},{"key":"R22-20260709","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","article-title":"Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges","volume":"41","author":"Hiemke","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R23-20260709","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00406-004-0556-4","article-title":"Risperidone plasma levels, clinical response and side-effects","volume":"255","author":"Riedel","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"R24-20260709","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00406-016-0736-z","article-title":"Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns","volume":"267","author":"Paulzen","year":"2017","journal-title":"Eur Arch Psychiatry Clin Neurosci"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:00:12Z","timestamp":1783609212000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":19,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001507","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"2026-03-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}